In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Affiliations

¹ University of Valencia and INCLIVA Biomedical Research Institute, Spain; Stanford University School of Medicine, Stanford, CA.
² John Ochsner Heart and Vascular Institute, Ochsner Clinical School The University of Queensland School of Medicine, New Orleans, LA.
³ University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain.
⁴ The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁵ University of Verona, Verona, Italy.

Comment

Fabian Sanchis-Gomar et al. Mayo Clin Proc. 2020 Jul.

. 2020 Jul;95(7):1553-1556.

doi: 10.1016/j.mayocp.2020.05.003. Epub 2020 May 21.

¹ University of Valencia and INCLIVA Biomedical Research Institute, Spain; Stanford University School of Medicine, Stanford, CA.
² John Ochsner Heart and Vascular Institute, Ochsner Clinical School The University of Queensland School of Medicine, New Orleans, LA.
³ University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain.
⁴ The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁵ University of Verona, Verona, Italy.

No abstract available

Comment on

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Sanchis-Gomar F, et al. Mayo Clin Proc. 2020 Jun;95(6):1222-1230. doi: 10.1016/j.mayocp.2020.03.026. Epub 2020 Apr 4. Mayo Clin Proc. 2020. PMID: 32376099 Free PMC article. Review.
Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Gersh FL. Gersh FL. Mayo Clin Proc. 2020 Jul;95(7):1552-1553. doi: 10.1016/j.mayocp.2020.05.001. Epub 2020 May 21. Mayo Clin Proc. 2020. PMID: 32622456 Free PMC article. No abstract available.

1. Diaz J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041. - PMC - PubMed
1. Burrell L.M., Risvanis J., Kubota E. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26(4):369–375. discussion 322-324. - PubMed
1. Walters T.E., Kalman J.M., Patel S.K., Mearns M., Velkoska E., Burrell L.M. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19(8):1280–1287. - PubMed
1. Ramchand J., Patel S.K., Srivastava P.M., Farouque O., Burrell L.M. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One. 2018;13(6):e0198144. - PMC - PubMed
1. Lippi G., Wong J., Henry B.M. Hypertension and its severity or mortality in coronavirus disease 2019 (COVID-19): a pooled analysis [published online ahead of print March 31, 2002] https://doi.org/10.20452/pamw.15272 Pol Arch Intern Med. - DOI - PubMed